Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity. (2021)

Cruz E, Sifniotis V, Sumer-Bayraktar Z, Reslan M, Wilkinson-White L, Cordwell S, Kayser V
Pharmaceutics, 2021 vol.13(11):1747

Loading ...

Export data

N-Linked structures

1

1235.1 Da

High-Mannose 1

Loading ...

1

1317.2 Da

Complex 1

Loading ...

1

1397.3 Da

High-Mannose 1

Loading ...

1

1463.4 Da

Complex 1

Loading ...

1

1520.4 Da

Complex 1

Loading ...

1

1584.5 Da

Hybrid 1

Loading ...

1

1600.5 Da

Hybrid 1

Loading ...

1

1625.5 Da

Complex 1

Loading ...

1

1682.6 Da

Complex 1

Loading ...

1

1721.5 Da

High-Mannose 1

Loading ...

1

1729.6 Da

Hybrid 1

Loading ...

1

1746.6 Da

Hybrid 1

Loading ...

1

1787.7 Da

Complex 1

Loading ...

1

1828.7 Da

Complex 1

Loading ...

1

1883.7 Da

High-Mannose 1

Loading ...

1

1891.7 Da

Hybrid 1

Loading ...

1

1932.8 Da

Complex 1

Loading ...

1

1974.8 Da

Complex 1

Loading ...

1

1990.8 Da

Complex 1

Loading ...

1

2078.9 Da

Complex 1

Loading ...

1

2120.0 Da

Complex 1

Loading ...

Cross-references

Pubmed : 34834161

DOI : 10.3390/pharmaceutics13111747

Compozitor : 10.3390/pharmaceutics13111747

Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity. (2021)

Cruz E, Sifniotis V, Sumer-Bayraktar Z, Reslan M, Wilkinson-White L, Cordwell S, Kayser VPharmaceutics, 2021 vol.13(11):1747

taxonomy 1

protein 8

source 1

structure 21

composition 21

site 8

peptide 2

N-Linked structures

5 x 2 x 1

High-Mannose 1

source 1

reference 1

site 3

peptide 1

3 x 4 x 1

Complex 1

source 1

reference 1

site 2

peptide 1

6 x 2 x 1

High-Mannose 1

source 1

reference 1

site 2

peptide 1

3 x 4 x 1 x 1

Complex 1

source 1

reference 1

site 8

peptide 2

3 x 5 x 1

Complex 1

source 1

reference 1

site 1

peptide 1

5 x 3 x 1 x 1

Hybrid 1

source 1

reference 1

site 1

peptide 1

6 x 3 x 1

Hybrid 1

source 1

reference 1

site 2

peptide 1

4 x 4 x 1 x 1

Complex 1

source 1

reference 1

site 8

peptide 2

4 x 5 x 1

Complex 1

source 1

reference 1

site 1

peptide 1

8 x 2 x 1

High-Mannose 1

source 1

reference 1

site 1

peptide 1

5 x 3 x 1 x 1

Hybrid 1

source 1

reference 1

site 1

peptide 1

6 x 3 x 1 x 1

Hybrid 1

source 1

reference 1

Cruz E, Sifniotis V, Sumer-Bayraktar Z, Reslan M, Wilkinson-White L, Cordwell S, Kayser V
Pharmaceutics, 2021 vol.13(11):1747

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1